Publication: Biological therapies for inherited diseases: social and bioethical considerations. Hemophilia as an example
Loading...
Official URL
Full text at PDC
Publication Date
2015-05
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Informa Healthcare
Citations
Exportar
Abstract
In hemophilia, advanced therapies are warranted from a conceptual and methodological standpoint. Current advanced therapy strategies are centered on the use of adeno-associated viral vectors, although problems related to immunogenicity and hepatotoxicity still remain.
Areas covered: Future clinical trials will have to scrupulously observe international bioethical standards in terms of patient selection, particularly children.
Patient recruitment rates are likely to remain low due to the stringent exclusion criteria usually imposed on the trial population regarding their hepatic and immunological markers and the presence ofviralcoinfection; and to the existence of an optimal palliative treatment.
Expert opinion: Accordingly, the results obtained are likely to be of low statistical significance, which could hinder their application to clinical practice. Another important issue is the degree to which society embraces these new emerging therapies. The unfamiliarity of society with these new methods, together with the many unresolved questions about them that remain, may threaten their acceptance not only by society at large but also by healthcare professionals, which would limit their translational application to clinical practice.
Description
UCM subjects
Unesco subjects
Keywords
Citation
1.Liras A, Segovia C, Gaban SA. Advanced therapies for the treatment of hemophilia: future perspectives. Orphanet J Rare Dis 2012;7:97 . This paper provides one of the most recent and exhaustive updates on advanced therapies applied to the treatment of hemophilia.
2.Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012;379:1447-56
3.Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013;19:e1-47
4.Liras A, Garcı´a-Trenchard R. Treatment for hemophilia: recombinant vs plasmaderived coagulation factors. Controversy and debate forever? An ethical medical challenge? Expert Rev Hematol 2013;6:489-92. .This article clearly expounds the debate between the use of recombinant factors and plasma-derived products in the treatment of hemophilia.
5.Schaub RG. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem Pharmacol 2011;82:91-8
6.De Mendoza C, Altisent C, Aznar JA, et al. Emerging Viral Infections. A Potential Threat for Blood Supply in the 21st Century. AIDS Rev 2012;14:279-89 ..A topical and exhaustive paper on the potential risk of emerging pathogen infection from viruses to prions in the treatment of hemophilia.
7.Hermans C, Brackmann HH, Schinco P, Auerswald G. The case for wider use of recombinant factor VIII concentrates.Crit Rev Oncol Hematol 2012;83:11-20
8.Franchini M, Coppola A, Rocino A, et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a:a 2013 update. Semin Thromb Hemost 2013;39:752-66 .An up-to-date review on the development of inhibitors in hemophilic patients.
9.Liras A. Advanced therapies for hemophilia: reality or fantasy? Expert Rev Hematol 2012;5:245-7
10.Jazwa A, Florczyk U, Jozkowicz A, Dulak J. Gene therapy on demand: site specific regulation of gene therapy. Gene 2013;525:229-38
11.High KA. Gene therapy for haemophilia: a long and winding road. J Thromb Haemost 2011;9(Suppl 1):2-11
12.Liras A, Gaban AS, Rodriguez-Merchan EC. Cartilage estoration in haemophilia: advanced therapies. Haemophilia 2012;18:672-9
13.Follenzi A, Benten D, Novikoff P, et al. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest 2008;118:935-45
14.Xu D, Alipio Z, Fink LM, et al.Phenotypic correction of murinehemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci USA 2009;106:808-13
15.Alipio Z, Adcock DM, Waner M, et al.Sustained factor VIII production in hemophiliac mice 1 year after engraftment with induced pluripotent stem cell-derived factor VIII producing endothelial cells. Blood Coagul Fibrinolysis 2010;21:502-4
16.Nathwani AC, Davidoff AM, Tuddenham EG. Prospects for gene therapy of haemophilia. Haemophilia 2004;10:309-18
17.Chuah MK, Nair N, VandenDriessche T. Recent progress in gene therapy for hemophilia. Hum Gene Ther 2012;23:557-65
18 Tuddenham E. Gene therapy for haemophilia B. Haemophilia 2012;18(Suppl 4):13-17
19.Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vectormediated gene transfer in hemophilia B.N Engl J Med 2011;365:2357-65 .First effective clinical trial on the use of gene therapy in patients with hemophilia B. Results were optimal both in terms of factor IX plasma levels and expression times.
20.High KA. The gene therapy journey for hemophilia: are we there yet? Blood 2012;120:4482-7
21. Romano G. Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy. ISRN Oncol 2012;2012:ID 616310
22.Wang W, Li W, Ma N, Steinhoff G. Non-viral gene delivery methods. Curr Pharm Biotechnol 2013;14:46-60
23.Li Z, Michael IP, Zhou D, et al. Simple piggyBac transposon-based mammalian cell expression system for inducible protein production. Proc Natl Acad Sci USA 2013;110:5004-9
24.Zaragosi LE, Billon N, Ailhaud G,Dani C. Nucleofection is a valuable transfection method for transient and stable transgene expression in adipose tissue-derived stem cells. Stem Cells 2007;25:790-7
25.Ragni MV, Sherman KE, Jordan JA. Viral pathogens. Haemophilia 2010;16(Suppl 5):40-6
26.Stoneman P, Sturgis P, Allum N. Exploring public discourses about emerging technologies through statistical clustering of open-ended survey questions. Public Underst Sci 2013;22:850-68
27.Olmedillas S, Garcia-Arranz M, Garcia-Olmo D, Liras A. A first approach to non-viral gene therapy for the treatment of hemophilia B, using human mesenchymal adipose-derived stem cells and nucleofection. 2014, in editorial revision
28.Gijsbers R, Ronen K, Vets S, et al. LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol Ther 2010;18:552-60
29.Vets S, De Rijck J, Brendel C, et al. Transient expression of an LEDGF/p75 chimera retargets lentivector integration and functionally rescues in a model for X-CGD. Mol Ther Nucl Acids 2013;2:e77
30.Du LM, Nurden P, Nurden AT, et al. Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun 2013;4:2773
31.Pikuła M, Marek-Trzonkowska N, Wardowska A, et al. Adipose tissuederived stem cells in clinical applications. Expert Opin Biol Ther 2013;13:1357-70
32.Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 2013;45:e54
33.Kasper CK, Buzin CH. Mosaicism and haemophilia. Haemophilia 2009;15:1181-6
34.Kimmelman J. Staunch protections: the ethics of haemophilia gene transfer research. Haemophilia 2008;14:5-14
35.Russell DW. AAV vectors, insertional mutagenesis, and cancer. Mol Ther 2007;15:1740-3
36.Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 2006;13:1031-49
37.Gallo-Penn A. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood 2001;97:107-13
38.Herzog RW, Dobrzynski E. Immune implications of gene therapy for hemophilia. Semin Thromb Hemost 2004;30:215-26
39.Lillicrap D, Vandendriessche T, High K. Cellular and genetic therapies for haemophilia. Haemophilia 2006;12:36-41
40.Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003;101:2963-72
41.High KA. Clinical gene transfer studies for hemophilia B. Semin Thromb Hemost 2004;30:257-67
42.Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-7
43.DiMichele D, Chuansumrit A, London AJ, et al. Ethical issues in haemophilia. Haemophilia 2006;12(Suppl 3):30-5
44.Chandy M. Ethics of haemophilia care in the developing world. Haemophilia 2002;8:439-40
45.Declaration of Helsinki. Available from: http://www.wma.net/en/20activities/10ethics/10helsinki/index.html [Last accessed 3 January 2015]
46.National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: U.S. Government PrintingOffice. 1978. Available from:http://videocast.nih.gov/pdf/ohrp_appendix_belmont_report_vol_2.pdf [Last accessed 3 January2015]
47.Matsui H, Shibata M, Brown B, et al. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells 2007;25(10):2660-9
48.Rogers GL, Herzog RW. Gene therapy for hemophilia. Front Biosci 2015;20:556-603 ..Latest review on the use of gene therapy in hemophilia showing the best options in terms of safety and efficacy.
49.Bornstein R, Macias MI, de la Torre P, et al. Human decidua-derived mesenchymal stromal cells differentiate into hepatic-like cells and form functional three-dimensional structures. Cytotherapy 2012;14(10):1182-92
50.Mannucci PM, Mancuso ME. Investigational drugs for coagulation disorders. Expert Opin Investig Drugs 2013;22(8):945-53
51.Lambing A, Kuriakose P, Kachalsky E. Liver transplantation in the haemophilia patient. Haemophilia 2012;18(2):300-3
52.Kessler C, Oldenburg J, Escuriola Ettingshausen C, et al. Spotlight on the human factor: building a foundation for the future of haemophilia A management. Haemophilia 2015;21(Suppl 1):1-12